Alzheimer's disease: Another target for heparin therapy

TheScientificWorldJournal

Volumn 9, Issue , 2009, Pages 891-908

  Bergamaschini, Luigi ^a   Rossi, Emanuela ^a   Vergani, Carlo ^a   De Simoni, Maria Grazia ^b  

^a UNIVERSITY OF MILAN   (Italy)

^b MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

Author keywords

Alzheimer's disease; Amyloid beta; Complement system; Contact kinin system; Heparin; Inflammation

Indexed keywords

AMYLOID BETA PROTEIN; APOLIPOPROTEIN E; GLYCOSAMINOGLYCAN; HEPARIN; KININ; METAL ION; CATION;

ALZHEIMER DISEASE; ANTIINFLAMMATORY ACTIVITY; BRAIN FUNCTION; COMPLEMENT SYSTEM; HEPARINIZATION; INFLAMMATION; NEUROFIBRILLARY TANGLE; PATHOGENESIS; REVIEW; SENILE PLAQUE; AMINO ACID SEQUENCE; CHEMISTRY; HUMAN; MOLECULAR GENETICS;

ALZHEIMER DISEASE; AMINO ACID SEQUENCE; AMYLOID BETA-PROTEIN; CATIONS; GLYCOSAMINOGLYCANS; HEPARIN; HUMANS; MOLECULAR SEQUENCE DATA;

EID: 70350749549     PISSN: None     EISSN: 1537744X     Source Type: Journal    
DOI: 10.1100/tsw.2009.100     Document Type: Review

References (212)

1. Selkoe, D.J. (1991) The molecular pathology of Alzheimer's disease. Neuron 6, 487-498.
2. Selkoe, D.J. (1997) Alzheimer's disease: genotypes, phenotypes, and treatments. Science 275, 630-631.
3. Jonsson, L. and Wimo, A. (2009) The cost of dementia in Europe: a review of the evidence, and methodological considerations. Pharmacoeconomics 27, 391-403.
4. Regland, B. and Gottfries, C.G. (1992) The role of amyloid beta-protein in Alzheimer's disease. Lancet 340, 467-469.
5. Jellinger, K.A. and Bancher, C. (1996) AD neuropathology. Neurology 46, 1186-1187.
6. Huang, H.C. and Jiang, Z.F. (2009) Accumulated amyloid-beta peptide and hyperphosphorylated tau protein: relationship and links in Alzheimer's disease. J. Alzheimers Dis. 16, 15-27.
7. Iqbal, K., Liu, F., Gong, C.X., Alonso, A.D., and Grundke-Iqbal, I. (2009) Mechanisms of tau-induced neurodegeneration. Acta Neuropathol. 118(1), 53-69.
8. Selkoe, D.J. (2001) Alzheimer's disease: genes, proteins, and therapy. Physiol. Rev. 81, 741-766.
9. Nathalie, P. and Jean-Noel, O. (2008) Processing of amyloid precursor protein and amyloid peptide neurotoxicity. Curr. Alzheimer Res. 5, 92-99.
10. Giulian, D., Haverkamp, L.J., Yu, J.H., Karshin, W., Tom, D., Li, J., Kirkpatrick, J., Kuo, L.M., and Roher, A.E. (1996) Specific domains of beta-amyloid from Alzheimer plaque elicit neuron killing in human microglia. J. Neurosci. 16, 6021-6037.
11. Kuo, Y.M., Emmerling, M.R., Vigo-Pelfrey, C., Kasunic, T.C., Kirkpatrick, J.B., Murdoch, G.H., Ball, M.J., and Roher, A.E. (1996) Water-soluble Abeta (N-40, N-42) oligomers in normal and Alzheimer disease brains. J. Biol. Chem. 271, 4077-4081.
12. Roher, A.E., Chaney, M.O., Kuo, Y.M., Webster, S.D., Stine, W.B., Haverkamp, L.J., Woods, A.S., Cotter, R.J., Tuohy, J.M., Krafft, G.A., Bonnell, B.S., and Emmerling, M.R. (1996) Morphology and toxicity of Abeta-(1-42) dimer derived from neuritic and vascular amyloid deposits of Alzheimer's disease. J. Biol. Chem. 271, 20631-20635.
13. Di Carlo, M. (2009) Beta amyloid peptide: from different aggregation forms to the activation of different biochemical pathways. Eur. Biophys. J. [Epub ahead of print]
14. Bu, G. (2009) Apolipoprotein E and its receptors in Alzheimer's disease: pathways, pathogenesis and therapy. Nat. Rev. 10, 333-344.
15. Kok, E., Haikonen, S., Luoto, T., Huhtala, H., Goebeler, S., Haapasalo, H., and Karhunen, P.J. (2009) Apolipoprotein E-dependent accumulation of Alzheimer disease-related lesions begins in middle age. Ann. Neurol. 65, 650-657.
16. Schipper, H.M. (2009) Apolipoprotein E: Implications for AD neurobiology, epidemiology and risk assessment. Neurobiol. Aging [Epub ahead of print]
17. Zhao, L., Lin, S., Bales, K.R., Gelfanova, V., Koger, D., Delong, C., Hale, J., Liu, F., Hunter, J.M., and Paul, S.M. (2009) Macrophage-mediated degradation of beta-amyloid via an apolipoprotein E isoform-dependent mechanism. J. Neurosci. 29, 3603-3612.
18. Zhong, N. and Weisgraber, K.H. (2009) Understanding the association of apolipoprotein E4 with Alzheimer disease: clues from its structure. J. Biol. Chem. 284, 6027-6031.
19. Finder, V.H. and Glockshuber, R. (2007) Amyloid-beta aggregation. Neurodegener. Dis. 4, 13-27.
20. Weiner, H.L. and Frenkel, D. (2006) Immunology and immunotherapy of Alzheimer's disease. Nat. Rev. Immunol. 6, 404-416.
21. Wilhelmus, M.M., de Waal, R.M., and Verbeek, M.M. (2007) Heat shock proteins and amateur chaperones in amyloid-Beta accumulation and clearance in Alzheimer's disease. Mol. Neurobiol. 35, 203-216.
22. Bates, K.A., Verdile, G., Li, Q.X., Ames, D., Hudson, P., Masters, C.L., and Martins, R.N. (2009) Clearance mechanisms of Alzheimer's amyloid-beta peptide: implications for therapeutic design and diagnostic tests. Mol. Psychiatry 14, 469-486.
23. Rochet, J.C. (2007) Novel therapeutic strategies for the treatment of protein-misfolding diseases. Expert Rev. Mol. Med. 9, 1-34.
24. Golde, T.E. (2006) Disease modifying therapy for AD? J. Neurochem. 99, 689-707.
25. Schmidt, R., Neff, F., Lampl, C., Benke, T., Anditsch, M., Bancher, C., Dal-Bianco, P., Reisecker, F., Marksteiner, J., Rainer, M., Kapeller, P., and Dodel, R. (2008) [Therapy of Alzheimer's disease: current status and future development]. Neuropsychiatrie 22, 153-171.
26. Ghosh, A.K., Gemma, S., and Tang, J. (2008) beta-Secretase as a therapeutic target for Alzheimer's disease. Neurotherapeutics 5, 399-408.
27. Ghosh, A.K., Kumaragurubaran, N., Hong, L., Koelsh, G., and Tang, J. (2008) Memapsin 2 (beta-secretase) inhibitors: drug development. Curr. Alzheimer Res. 5, 121-131.
28. Guo, T. and Hobbs, D.W. (2006) Development of BACE1 inhibitors for Alzheimer's disease. Curr. Med. Chem. 13, 1811-1829.
29. Serneels, L., Van Biervliet, J., Craessaerts, K., Dejaegere, T., Horre, K., Van Houtvin, T., Esselmann, H., Paul, S., Schafer, M.K., Berezovska, O., Hyman, B.T., Sprangers, B., Sciot, R., Moons, L., Jucker, M., Yang, Z., May, P.C., Karran, E., Wiltfang, J., D'Hooge, R., and De Strooper, B. (2009) gamma-Secretase heterogeneity in the Aph1 subunit: relevance for Alzheimer's disease. Science 324, 639-642.
30. Tomita, T. (2009) Secretase inhibitors and modulators for Alzheimer's disease treatment. Expert Rev. Neurother. 9, 661-679.
31. Boimel, M., Grigoriadis, N., Lourbopoulos, A., Touloumi, O., Rosenmann, D., Abramsky, O., and Rosenmann, H. (2009) Statins reduce the neurofibrillary tangle burden in a mouse model of tauopathy. J. Neuropathol. Exp. Neurol. 68, 314-325.
32. Haag, M.D., Hofman, A., Koudstaal, P.J., Stricker, B.H., and Breteler, M.M. (2009) Statins are associated with a reduced risk of Alzheimer disease regardless of lipophilicity. The Rotterdam Study. J. Neurol. Neurosurg. Psychiatry 80, 13-17.
33. Parsons, R.B., Farrant, J.K., Price, G.C., Subramaniam, D., and Austen, B.M. (2007) Regulation of the lipidation of beta-secretase by statins. Biochem. Soc. Trans. 35, 577-582.
34. Siegel, G.J., Chauhan, N.B., Feinstein, D.L., Li, G., Larson, E.B., Breitner, J.C., and Montine, T.J. (2008) Statin therapy is associated with reduced neuropathologic changes of Alzheimer disease. Neurology 71, 383; author reply 383.
35. Arvanitakis, Z., Schneider, J.A., Wilson, R.S., Bienias, J.L., Kelly, J.F., Evans, D.A., and Bennett, D.A. (2008) Statins, incident Alzheimer disease, change in cognitive function, and neuropathology. Neurology 70, 1795-1802.
36. Wisniewski, T. and Konietzko, U. (2008) Amyloid-beta immunisation for Alzheimer's disease. Lancet Neurol. 7, 805-811.
37. Schenk, D. (2002) Amyloid-beta immunotherapy for Alzheimer's disease: the end of the beginning. Nat. Rev. 3, 824-828.
38. Morgan, D. (2006) Immunotherapy for Alzheimer's disease. J. Alzheimers Dis. 9, 425-432.
39. Haass, C. (2002) New hope for Alzheimer disease vaccine. Nat. Med. 8, 1195-1196.
40. Levites, Y., Das, P., Price, R.W., Rochette, M.J., Kostura, L.A., McGowan, E.M., Murphy, M.P., and Golde, T.E. (2006) Anti-Abeta42- and anti-Abeta40-specific mAbs attenuate amyloid deposition in an Alzheimer disease mouse model. J. Clin. Invest. 116, 193-201.
41. Tanzi, R.E. and Bertram, L. (2005) Twenty years of the Alzheimer's disease amyloid hypothesis: a genetic perspective. Cell 120, 545-555.
42. Mormino, E.C., Kluth, J.T., Madison, C.M., Rabinovici, G.D., Baker, S.L., Miller, B.L., Koeppe, R.A., Mathis, C.A., Weiner, M.W., and Jagust, W.J. (2009) Episodic memory loss is related to hippocampal-mediated beta-amyloid deposition in elderly subjects. Brain 132, 1310-1323.
43. Castellani, R.J., Lee, H.G., Zhu, X., Perry, G., and Smith, M.A. (2008) Alzheimer disease pathology as a host response. J. Neuropathol. Exp. Neurol. 67, 523-531.
44. Hardy, J. (2009) The amyloid hypothesis for Alzheimer's disease: a critical reappraisal. J. Neurochem. 110(4), 1129-1134.
45. Salminen, A., Ojala, J., Kauppinen, A., Kaarniranta, K., and Suuronen, T. (2009) Inflammation in Alzheimer's disease: amyloid-beta oligomers trigger innate immunity defence via pattern recognition receptors. Prog. Neurobiol. 87, 181-194.
46. Beckman, M., Holsinger, R.M., and Small, D.H. (2006) Heparin activates beta-secretase (BACE1) of Alzheimer's disease and increases autocatalysis of the enzyme. Biochemistry 45, 6703-6714.
47. Bergamaschini, L., Donarini, C., Foddi, C., Gobbo, G., Parnetti, L., and Agostoni, A. (2001) The region 1-11 of Alzheimer amyloid-beta is critical for activation of contact-kinin system. Neurobiol. Aging 22, 63-69.
48. Bergamaschini, L., Donarini, C., Rossi, E., De Luigi, A., Vergani, C., and De Simoni, M.G. (2002) Heparin attenuates cytotoxic and inflammatory activity of Alzheimer amyloid-beta in vitro. Neurobiol. Aging 23, 531-536.
49. Bergamaschini, L., Rossi, E., Storini, C., Pizzimenti, S., Distaso, M., Perego, C., De Luigi, A., Vergani, C., and De Simoni, M.G. (2004) Peripheral treatment with enoxaparin, a low molecular weight heparin, reduces plaques and beta-amyloid accumulation in a mouse model of Alzheimer's disease. J. Neurosci. 24, 4181-4186.
50. Leveugle, B., Ding, W., Laurence, F., Dehouck, M.P., Scanameo, A., Cecchelli, R., and Fillit, H. (1998) Heparin oligosaccharides that pass the blood-brain barrier inhibit beta-amyloid precursor protein secretion and heparin binding to beta-amyloid peptide. J. Neurochem. 70, 736-744.
51. Leveugle, B. and Fillit, H. (1994) Proteoglycans and the acute-phase response in Alzheimer's disease brain. Mol. Neurobiol. 9, 25-32.
52. Leveugle, B., Scanameo, A., Ding, W., and Fillit, H. (1994) Binding of heparan sulfate glycosaminoglycan to betaamyloid peptide: inhibition by potentially therapeutic polysulfated compounds. Neuroreport 5, 1389-1392.
53. Tyrrell, D.J., Horne, A.P., Holme, K.R., Preuss, J.M., and Page, C.P. (1999) Heparin in inflammation: potential therapeutic applications beyond anticoagulation. Adv. Pharmacol. 46, 151-208.
54. Watson, D.J., Lander, A.D., and Selkoe, D.J. (1997) Heparin-binding properties of the amyloidogenic peptides Abeta and amylin. Dependence on aggregation state and inhibition by Congo red. J. Biol. Chem. 272, 31617-31624.
55. Ma, Q., Cornelli, U., Hanin, I., Jeske, W.P., Linhardt, R.J., Walenga, J.M., Fareed, J., and Lee, J.M. (2007) Heparin oligosaccharides as potential therapeutic agents in senile dementia. Curr. Pharm. Des. 13, 1607-1616.
56. Patey, S.J., Edwards, E.A., Yates, E.A., and Turnbull, J.E. (2008) Engineered heparins: novel beta-secretase inhibitors as potential Alzheimer's disease therapeutics. Neurodegener. Dis. 5, 197-199.
57. Gandhi, N.S. and Mancera, R.L. (2008) The structure of glycosaminoglycans and their interactions with proteins. Chem. Biol. Drug Des. 72, 455-482.
58. Shirai, K. and Chaudhary, U.B. (2007) Use of low molecular weight heparin and aminocaproic acid in chronic DIC associated with prostate cancer - a case report. TheScientificWorldJOURNAL 7, 753-755.
59. Casu, B. (1989) Structure and biological activity of mammalian glycosaminoglycans. Mod. Probl. Pharmacopsychiatry 23, 56-67.
60. Bos, I.G., van Mierlo, G.J., Bleeker, W.K., Rigter, G.M., te Velthuis, H., Dickneite, G., and Hack, C.E. (2001) The potentiation of human C1-inhibitor by dextran sulphate is transient in vivo: studies in a rat model. Int. Immunopharmacol. 1, 1583-1595.
61. Burger, R., Hadding, U., Schorlemmer, H.U., Brade, V., and Bitter-Suermann, D. (1975) Dextran sulphate: a synthetic activator of C3 via the alternative pathway. I. Influence of molecular size and degree of sulphation on the activation potency. Immunology 29, 549-554.
62. Meri, S. and Pangburn, M.K. (1994) Regulation of alternative pathway complement activation by glycosaminoglycans: specificity of the polyanion binding site on factor H. Biochem. Biophys. Res. Commun. 198, 52-59.
63. Quigg, R.J. (1992) Inhibition of the alternative pathway of complement by glomerular chondroitin sulphate proteoglycan. Immunology 76, 373-377.
64. Young, E. (2008) The anti-inflammatory effects of heparin and related compounds. Thromb. Res. 122, 743-752.
65. Hirsh, J. (1991) Heparin. N. Engl. J. Med. 324, 1565-1574.
66. Weitz, J.I. (1997) Low-molecular-weight heparins. N. Engl. J. Med. 337, 688-698.
67. Lobb, R.R. (1988) Clinical applications of heparin-binding growth factors. Eur. J. Clin. Invest. 18, 321-336.
68. Casu, B., Vlodavsky, I., and Sanderson, R.D. (2008) Non-anticoagulant heparins and inhibition of cancer. Pathophysiol. Haemost. Thromb. 36, 195-203.
69. Mitsi, M., Forsten-Williams, K., Gopalakrishnan, M., and Nugent, M.A. (2008) A catalytic role of heparin within the extracellular matrix. J. Biol. Chem. 283, 34796-34807.
70. Sugaya, N., Habuchi, H., Nagai, N., Ashikari-Hada, S., and Kimata, K. (2008) 6-O-sulfation of heparan sulfate differentially regulates various fibroblast growth factor-dependent signalings in culture. J. Biol. Chem. 283, 10366-10376.
71. Trindade, E.S., Oliver, C., Jamur, M.C., Rocha, H.A., Franco, C.R., Boucas, R.I., Jarrouge, T.R., Pinhal, M.A., Tersariol, I.L., Gouvea, T.C., Dietrich, C.P., and Nader, H.B. (2008) The binding of heparin to the extracellular matrix of endothelial cells up-regulates the synthesis of an antithrombotic heparan sulfate proteoglycan. J. Cell. Physiol. 217, 328-337.
72. Beisiegel, U., Weber, W., and Bengtsson-Olivecrona, G. (1991) Lipoprotein lipase enhances the binding of chylomicrons to low density lipoprotein receptor-related protein. Proc. Natl. Acad. Sci. U. S. A. 88, 8342-8346.
73. Chevreuil, O., Hultin, M., Ostergaard, P., and Olivecrona, T. (1993) Biphasic effects of low-molecular-weight and conventional heparins on chylomicron clearance in rats. Arterioscler. Thromb. 13, 1397-1403.
74. Chevreuil, O., Hultin, M., Ostergaard, P., and Olivecrona, T. (1993) Depletion of lipoprotein lipase after heparin administration. Arterioscler. Thromb. 13, 1391-1396.
75. Fan, T.C., Fang, S.L., Hwang, C.S., Hsu, C.Y., Lu, X.A., Hung, S.C., Lin, S.C., and Chang, M.D. (2008) Characterization of molecular interactions between eosinophil cationic protein and heparin. J. Biol. Chem. 283, 25468-25474.
76. Hochart, H., Jenkins, P.V., Smith, O.P., and White, B. (2006) Low-molecular weight and unfractionated heparins induce a downregulation of inflammation: decreased levels of proinflammatory cytokines and nuclear factor-kappaB in LPS-stimulated human monocytes. Br. J. Haematol. 133, 62-67.
77. Gao, Y., Li, N., Fei, R., Chen, Z., Zheng, S., and Zeng, X. (2005) P-Selectin-mediated acute inflammation can be blocked by chemically modified heparin, RO-heparin. Mol. Cells 19, 350-355.
78. Mahoney, D.J., Mulloy, B., Forster, M.J., Blundell, C.D., Fries, E., Milner, C.M., and Day, A.J. (2005) Characterization of the interaction between tumor necrosis factor-stimulated gene-6 and heparin: implications for the inhibition of plasmin in extracellular matrix microenvironments. J. Biol. Chem. 280, 27044-27055.
79. Johnson, Z., Kosco-Vilbois, M.H., Herren, S., Cirillo, R., Muzio, V., Zaratin, P., Carbonatto, M., Mack, M., Smailbegovic, A., Rose, M., Lever, R., Page, C., Wells, T.N., and Proudfoot, A.E. (2004) Interference with heparin binding and oligomerization creates a novel anti-inflammatory strategy targeting the chemokine system. J. Immunol. 173, 5776-5785.
80. Elsayed, E. and Becker, R.C. (2003) The impact of heparin compounds on cellular inflammatory responses: a construct for future investigation and pharmaceutical development. J. Thromb. Thrombolysis 15, 11-18.
81. Culley, F.J., Fadlon, E.J., Kirchem, A., Williams, T.J., Jose, P.J., and Pease, J.E. (2003) Proteoglycans are potent modulators of the biological responses of eosinophils to chemokines. Eur. J. Immunol. 33, 1302-1310.
82. Fabiana Alberto, M., Giaquinta Romero, D., Lazzari, M., and Calabrese, G.C. (2008) Antithrombotic and anticomplementary properties of a very low molecular mass dermatan sulfate. Thromb. Res. 122, 109-116.
83. Hellwage, J., Jokiranta, T.S., Koistinen, V., Vaarala, O., Meri, S., and Zipfel, P.F. (1999) Functional properties of complement factor H-related proteins FHR-3 and FHR-4: binding to the C3d region of C3b and differential regulation by heparin. FEBS Lett. 462, 345-352.
84. Murray-Rust, T.A., Kerr, F.K., Thomas, A.R., Wu, T., Tang, Y., Ong, P.C., Quinsey, N.S., Whisstock, J.C., Wagenaar-Bos, I.G., Freeman, C., and Pike, R.N. (2009) Modulation of the proteolytic activity of the complement protease C1s by polyanions: implications for polyanion-mediated acceleration of interaction between C1s and SERPING1. Biochem. J. 422(2), 295-303.
85. Perkins, S.J. and Goodship, T.H. (2002) Molecular modelling of the C-terminal domains of factor H of human complement: a correlation between haemolytic uraemic syndrome and a predicted heparin binding site. J. Mol. Biol. 316, 217-224.
86. Schmidt, C.Q., Herbert, A.P., Kavanagh, D., Gandy, C., Fenton, C.J., Blaum, B.S., Lyon, M., Uhrin, D., and Barlow, P.N. (2008) A new map of glycosaminoglycan and C3b binding sites on factor H. J. Immunol. 181, 2610-2619.
87. Yang, L., Sun, M.F., Gailani, D., and Rezaie, A.R. (2009) Characterization of a heparin-binding site on the catalytic domain of factor XIa: mechanism of heparin acceleration of factor XIa inhibition by the serpins antithrombin and C1-inhibitor. Biochemistry 48, 1517-1524.
88. Krishnamoorthy, M., Heimburg-Molinaro, J., Bargo, A.M., Nash, R.J., and Nash, R.J. (2009) Heparin binding epidermal growth factor-like growth factor and PD169316 prevent apoptosis in mouse embryonic stem cells. J. Biochem. 145, 177-184.
89. Widlak, P. and Garrard, W.T. (2006) The apoptotic endonuclease DFF40/CAD is inhibited by RNA, heparin and other polyanions. Apoptosis 11, 1331-1337.
90. Gebska, M.A., Titley, I., Paterson, H.F., Morilla, R.M., Davies, D.C., Gruszka-Westwood, A.M., Kakkar, V.V., Eccles, S., and Scully, M.F. (2002) High-affinity binding sites for heparin generated on leukocytes during apoptosis arise from nuclear structures segregated during cell death. Blood 99, 2221-2227.
91. Vassar, R. (2005) beta-Secretase, APP and Abeta in Alzheimer's disease. Subcell. Biochem. 38, 79-103.
92. Ewers, M., Zhong, Z., Burger, K., Wallin, A., Blennow, K., Teipel, S.J., Shen, Y., and Hampel, H. (2008) Increased CSF-BACE 1 activity is associated with ApoE-epsilon 4 genotype in subjects with mild cognitive impairment and Alzheimer's disease. Brain 131, 1252-1258.
93. Scholefield, Z., Yates, E.A., Wayne, G., Amour, A., McDowell, W., and Turnbull, J.E. (2003) Heparan sulfate regulates amyloid precursor protein processing by BACE1, the Alzheimer's beta-ecretase. J. Cell Biol. 163, 97-107.
94. Bergamaschini, L., Donarini, C., Gobbo, G., Parnetti, L., and Gallai, V. (2001) Activation of complement and contact system in Alzheimer's disease. Mech. Ageing Dev. 122, 1971-1983.
95. Velazquez, P., Cribbs, D.H., Poulos, T.L., and Tenner, A.J. (1997) Aspartate residue 7 in amyloid beta-protein is critical for classical complement pathway activation: implications for Alzheimer's disease pathogenesis. Nat. Med. 3, 77-79.
96. Webster, S., Bonnell, B., and Rogers, J. (1997) Charge-based binding of complement component C1q to the Alzheimer amyloid beta-peptide. Am. J. Pathol. 150, 1531-1536.
97. Pollack, S.J., Sadler, I.I., Hawtin, S.R., Tailor, V.J., and Shearman, M.S. (1995) Sulfonated dyes attenuate the toxic effects of beta-amyloid in a structure-specific fashion. Neurosci. Lett. 197, 211-214.
98. Pollack, S.J., Sadler, I.I., Hawtin, S.R., Tailor, V.J., and Shearman, M.S. (1995) Sulfated glycosaminoglycans and dyes attenuate the neurotoxic effects of beta-amyloid in rat PC12 cells. Neurosci. Lett. 184, 113-116.
99. Woods, A.G., Cribbs, D.H., Whittemore, E.R., and Cotman, C.W. (1995) Heparan sulfate and chondroitin sulfate glycosaminoglycan attenuate beta-amyloid(25-35) induced neurodegeneration in cultured hippocampal neurons. Brain Res. 697, 53-62.
100. Atwood, C.S., Scarpa, R.C., Huang, X., Moir, R.D., Jones, W.D., Fairlie, D.P., Tanzi, R.E., and Bush, A.I. (2000) Characterization of copper interactions with Alzheimer amyloid beta peptides: identification of an attomolar-affinity copper binding site on amyloid beta1-42. J. Neurochem. 75, 1219-1233.
101. Danielsson, J., Pierattelli, R., Banci, L., and Graslund, A. (2007) High-resolution NMR studies of the zinc-binding site of the Alzheimer's amyloid beta-peptide. FEBS J. 274, 46-59.
102. House, E., Collingwood, J., Khan, A., Korchazkina, O., Berthon, G., and Exley, C. (2004) Aluminium, iron, zinc and copper influence the in vitro formation of amyloid fibrils of Abeta42 in a manner which may have consequences for metal chelation therapy in Alzheimer's disease. J. Alzheimers Dis. 6, 291-301.
103. Curtain, C.C., Ali, F.E., Smith, D.G., Bush, A.I., Masters, C.L., and Barnham, K.J. (2003) Metal ions, pH, and cholesterol regulate the interactions of Alzheimer's disease amyloid-beta peptide with membrane lipid. J. Biol. Chem. 278, 2977-2982.
104. Esler, W.P., Stimson, E.R., Jennings, J.M., Ghilardi, J.R., Mantyh, P.W., and Maggio, J.E. (1996) Zinc-induced aggregation of human and rat beta-amyloid peptides in vitro. J. Neurochem. 66, 723-732.
105. Karr, J.W., Kaupp, L.J., and Szalai, V.A. (2004) Amyloid-beta binds Cu2+ in a mononuclear metal ion binding site. J. Am. Chem. Soc. 126, 13534-13538.
106. Kowalik-Jankowska, T., Ruta-Dolejsz, M., Wisniewska, K., and Lankiewicz, L. (2001) Cu(II) interaction with Nterminal fragments of human and mouse beta-amyloid peptide. J. Inorg. Biochem. 86, 535-545.
107. Liu, S.T., Howlett, G., and Barrow, C.J. (1999) Histidine-13 is a crucial residue in the zinc ion-induced aggregation of the A beta peptide of Alzheimer's disease. Biochemistry 38, 9373-9378.
108. Van Nostrand, W.E. (1995) Zinc (II) selectively enhances the inhibition of coagulation factor XIa by protease nexin-2/amyloid beta-protein precursor. Thromb. Res. 78, 43-53.
109. Lovell, M.A., Robertson, J.D., Teesdale, W.J., Campbell, J.L., and Markesbery, W.R. (1998) Copper, iron and zinc in Alzheimer's disease senile plaques. J. Neurol. Sci. 158, 47-52.
110. Basun, H., Forssell, L.G., Wetterberg, L., and Winblad, B. (1991) Metals and trace elements in plasma and cerebrospinal fluid in normal aging and Alzheimer's disease. J. Neural Transm. 3, 231-258.
111. Bush, A.I., Pettingell, W.H., Jr., de Paradis, M., Tanzi, R.E., and Wasco, W. (1994) The amyloid beta-protein precursor and its mammalian homologues. Evidence for a zinc-modulated heparin-binding superfamily. J. Biol. Chem. 269, 26618-26621.
112. Bush, A.I., Pettingell, W.H., Multhaup, G., d Paradis, M., Vonsattel, J.P., Gusella, J.F., Beyreuther, K., Masters, C.L., and Tanzi, R.E. (1994) Rapid induction of Alzheimer A beta amyloid formation by zinc. Science 265, 1464-1467.
113. Bush, A.I. and Tanzi, R.E. (2008) Therapeutics for Alzheimer's disease based on the metal hypothesis. Neurotherapeutics 5, 421-432.
114. Rudd, T.R., Skidmore, M.A., Guimond, S.E., Guerrini, M., Cosentino, C., Edge, R., Brown, A., Clarke, D.T., Torri, G., Turnbull, J.E., Nichols, R.J., Fernig, D.G., and Yates, E.A. (2008) Site-specific interactions of copper(II) ions with heparin revealed with complementary (SRCD, NMR, FTIR and EPR) spectroscopic techniques. Carbohydr. Res. 343, 2184-2193.
115. Grant, D., Long, W.F., and Williamson, F.B. (1992) A potentiometric titration study of the interaction of heparin with metal cations. Biochem. J. 285 (Pt 2), 477-480.
116. Fu, C.L. and Horn, M.K., 3rd (2002) Histidine-rich glycoprotein plus zinc to neutralize heparin. J. Lab. Clin. Med. 139, 211-217.
117. Bush, A.I., Multhaup, G., Moir, R.D., Williamson, T.G., Small, D.H., Rumble, B., Pollwein, P., Beyreuther, K., and Masters, C.L. (1993) A novel zinc(II) binding site modulates the function of the beta A4 amyloid protein precursor of Alzheimer's disease. J. Biol. Chem. 268, 16109-16112.
118. Antonyuk, S.V., Strange, R.W., Marklund, S.L., and Hasnain, S.S. (2009) The structure of human extracellular copper-zinc superoxide dismutase at 1.7 A resolution: insights into heparin and collagen binding. J. Mol. Biol. 388, 310-326.
119. Beckman, J.S., Beckman, T.W., Chen, J., Marshall, P.A., and Freeman, B.A. (1990) Apparent hydroxyl radical production by peroxynitrite: implications for endothelial injury from nitric oxide and superoxide. Proc. Natl. Acad. Sci. U. S. A. 87, 1620-1624.
120. Carlsson, L.M., Jonsson, J., Edlund, T., and Marklund, S.L. (1995) Mice lacking extracellular superoxide dismutase are more sensitive to hyperoxia. Proc. Natl. Acad. Sci. U. S. A. 92, 6264-6268.
121. Jung, O., Marklund, S.L., Geiger, H., Pedrazzini, T., Busse, R., and Brandes, R.P. (2003) Extracellular superoxide dismutase is a major determinant of nitric oxide bioavailability: in vivo and ex vivo evidence from ecSOD-deficient mice. Circ. Res. 93, 622-629.
122. Kim, H.W., Lin, A., Guldberg, R.E., Ushio-Fukai, M., and Fukai, T. (2007) Essential role of extracellular SOD in reparative neovascularization induced by hindlimb ischemia. Circ. Res. 101, 409-419.
123. Levin, E.D., Brady, T.C., Hochrein, E.C., Oury, T.D., Jonsson, L.M., Marklund, S.L., and Crapo, J.D. (1998) Molecular manipulations of extracellular superoxide dismutase: functional importance for learning. Behav. Genet. 28, 381-390.
124. Juul, K., Tybjaerg-Hansen, A., Marklund, S., Heegaard, N.H., Steffensen, R., Sillesen, H., Jensen, G., and Nordestgaard, B.G. (2004) Genetically reduced antioxidative protection and increased ischemic heart disease risk: The Copenhagen City Heart Study. Circulation 109, 59-65.
125. Akiyama, H., Barger, S., Barnum, S., Bradt, B., Bauer, J., Cole, G.M., Cooper, N.R., Eikelenboom, P., Emmerling, M., Fiebich, B.L., Finch, C.E., Frautschy, S., Griffin, W.S., Hampel, H., Hull, M., Landreth, G., Lue, L., Mrak, R., Mackenzie, I.R., McGeer, P.L., O'Banion, M.K., Pachter, J., Pasinetti, G., Plata-Salaman, C., Rogers, J., Rydel, R., Shen, Y., Streit, W., Strohmeyer, R., Tooyoma, I., Van Muiswinkel, F.L., Veerhuis, R., Walker, D., Webster, S., Wegrzyniak, B., Wenk, G., and Wyss-Coray, T. (2000) Inflammation and Alzheimer's disease. Neurobiol. Aging 21, 383-421.
126. Eikelenboom, P., Rozemuller, J.M., Kraal, G., Stam, F.C., McBride, P.A., Bruce, M.E., and Fraser, H. (1991) Cerebral amyloid plaques in Alzheimer's disease but not in scrapie-affected mice are closely associated with a local inflammatory process. Virchows Arch. B Cell Pathol. Incl. Mol. Pathol. 60, 329-336.
127. Emmerling, M.R., Watson, M.D., Raby, C.A., and Spiegel, K. (2000) The role of complement in Alzheimer's disease pathology. Biochim. Biophys. Acta 1502, 158-171.
128. McGeer, E.G. and McGeer, P.L. (1999) Brain inflammation in Alzheimer disease and the therapeutic implications. Curr. Pharm. Des. 5, 821-836.
129. McGeer, P.L. and McGeer, E.G. (1999) Inflammation of the brain in Alzheimer's disease: implications for therapy. J. Leukoc. Biol. 65, 409-415.
130. Walport, M.J. (2001) Complement. Second of two parts. N. Engl. J. Med. 344, 1140-1144.
131. Walport, M.J. (2001) Complement. First of two parts. N. Engl. J. Med. 344, 1058-1066.
132. Head, E., Azizeh, B.Y., Lott, I.T., Tenner, A.J., Cotman, C.W., and Cribbs, D.H. (2001) Complement association with neurons and beta-amyloid deposition in the brains of aged individuals with Down Syndrome. Neurobiol. Dis. 8, 252-265.
133. Veerhuis, R., van der Valk, P., Janssen, I., Zhan, S.S., Van Nostrand, W.E., and Eikelenboom, P. (1995) Complement activation in amyloid plaques in Alzheimer's disease brains does not proceed further than C3. Virchows Arch. 426, 603-610.
134. Sjoberg, A.P., Trouw, L.A., and Blom, A.M. (2009) Complement activation and inhibition: a delicate balance. Trends Immunol. 30, 83-90.
135. Ramaglia, V., King, R.H., Morgan, B.P., and Baas, F. (2009) Deficiency of the complement regulator CD59a exacerbates Wallerian degeneration. Mol. Immunol. 46, 1892-1896.
136. Beinrohr, L., Dobo, J., Zavodszky, P., and Gal, P. (2008) C1, MBL-MASPs and C1-inhibitor: novel approaches for targeting complement-mediated inflammation. Trends Mol. Med. 14, 511-521.
137. Tei, R., Kaido, T., Nakase, H., and Sakaki, T. (2008) Protective effect of C1 esterase inhibitor on acute traumatic spinal cord injury in the rat. Neurol. Res. 30, 761-767.
138. Maier, M., Peng, Y., Jiang, L., Seabrook, T.J., Carroll, M.C., and Lemere, C.A. (2008) Complement C3 deficiency leads to accelerated amyloid beta plaque deposition and neurodegeneration and modulation of the microglia/macrophage phenotype in amyloid precursor protein transgenic mice. J. Neurosci. 28, 6333-6341.
139. Griffiths, M., Neal, J.W., and Gasque, P. (2007) Innate immunity and protective neuroinflammation: new emphasis on the role of neuroimmune regulatory proteins. Int. Rev. Neurobiol. 82, 29-55.
140. Woodruff, T.M., Crane, J.W., Proctor, L.M., Buller, K.M., Shek, A.B., de Vos, K., Pollitt, S., Williams, H.M., Shiels, I.A., Monk, P.N., and Taylor, S.M. (2006) Therapeutic activity of C5a receptor antagonists in a rat model of neurodegeneration. FASEB J. 20, 1407-1417.
141. Bonifati, D.M. and Kishore, U. (2007) Role of complement in neurodegeneration and neuroinflammation. Mol. Immunol. 44, 999-1010.
142. Leinhase, I., Schmidt, O.I., Thurman, J.M., Hossini, A.M., Rozanski, M., Taha, M.E., Scheffler, A., John, T., Smith, W.R., Holers, V.M., and Stahel, P.F. (2006) Pharmacological complement inhibition at the C3 convertase level promotes neuronal survival, neuroprotective intracerebral gene expression, and neurological outcome after traumatic brain injury. Exp. Neurol. 199, 454-464.
143. Storini, C., Rossi, E., Marrella, V., Distaso, M., Veerhuis, R., Vergani, C., Bergamaschini, L., and De Simoni, M.G. (2005) C1-inhibitor protects against brain ischemia-reperfusion injury via inhibition of cell recruitment and inflammation. Neurobiol. Dis. 19, 10-17.
144. de Jonge, R.R., van Schaik, I.N., Vreijling, J.P., Troost, D., and Baas, F. (2004) Expression of complement components in the peripheral nervous system. Hum. Mol. Genet. 13, 295-302.
145. van Beek, J., Elward, K., and Gasque, P. (2003) Activation of complement in the central nervous system: roles in neurodegeneration and neuroprotection. Ann. N. Y. Acad. Sci. 992, 56-71.
146. Yang, L.B., Li, R., Meri, S., Rogers, J., and Shen, Y. (2000) Deficiency of complement defense protein CD59 may contribute to neurodegeneration in Alzheimer's disease. J. Neurosci. 20, 7505-7509.
147. Gasque, P., Dean, Y.D., McGreal, E.P., VanBeek, J., and Morgan, B.P. (2000) Complement components of the innate immune system in health and disease in the CNS. Immunopharmacology 49, 171-186.
148. Barrington, R., Zhang, M., Fischer, M., and Carroll, M.C. (2001) The role of complement in inflammation and adaptive immunity. Immunol. Rev. 180, 5-15.
149. Eikelenboom, P. and Stam, F.C. (1984) An immunohistochemical study on cerebral vascular and senile plaque amyloid in Alzheimer's dementia. Virchows Arch. B Cell Pathol. Incl. Mol. Pathol. 47, 17-25.
150. Stoltzner, S.E., Grenfell, T.J., Mori, C., Wisniewski, K.E., Wisniewski, T.M., Selkoe, D.J., and Lemere, C.A. (2000) Temporal accrual of complement proteins in amyloid plaques in Down's syndrome with Alzheimer's disease. Am. J. Pathol. 156, 489-499.
151. Strohmeyer, R., Shen, Y., and Rogers, J. (2000) Detection of complement alternative pathway mRNA and proteins in the Alzheimer's disease brain. Brain Res. Mol. Brain Res. 81, 7-18.
152. Webster, S., Bradt, B., Rogers, J., and Cooper, N. (1997) Aggregation state-dependent activation of the classical complement pathway by the amyloid beta peptide. J. Neurochem. 69, 388-398.
153. Webster, S., Lue, L.F., Brachova, L., Tenner, A.J., McGeer, P.L., Terai, K., Walker, D.G., Bradt, B., Cooper, N.R., and Rogers, J. (1997) Molecular and cellular characterization of the membrane attack complex, C5b-9, in Alzheimer's disease. Neurobiol. Aging 18, 415-421.
154. Yasojima, K., Schwab, C., McGeer, E.G., and McGeer, P.L. (1999) Up-regulated production and activation of the complement system in Alzheimer's disease brain. Am. J. Pathol. 154, 927-936.
155. Zhou, J., Fonseca, M.I., Pisalyaput, K., and Tenner, A.J. (2008) Complement C3 and C4 expression in C1q sufficient and deficient mouse models of Alzheimer's disease. J. Neurochem. 106, 2080-2092.
156. Tenner, A.J. (2001) Complement in Alzheimer's disease: opportunities for modulating protective and pathogenic events. Neurobiol. Aging 22, 849-861.
157. Webster, S.D., Yang, A.J., Margol, L., Garzon-Rodriguez, W., Glabe, C.G., and Tenner, A.J. (2000) Complement component C1q modulates the phagocytosis of Abeta by microglia. Exp. Neurol. 161, 127-138.
158. Jiang, H., Burdick, D., Glabe, C.G., Cotman, C.W., and Tenner, A.J. (1994) beta-Amyloid activates complement by binding to a specific region of the collagen-like domain of the C1q A chain. J. Immunol. 152, 5050-5059.
159. Rogers, J., Cooper, N.R., Webster, S., Schultz, J., McGeer, P.L., Styren, S.D., Civin, W.H., Brachova, L., Bradt, B., Ward, P., et al. (1992) Complement activation by beta-amyloid in Alzheimer disease. Proc. Natl. Acad. Sci. U. S. A. 89, 10016-10020.
160. Tacnet-Delorme, P., Chevallier, S., and Arlaud, G.J. (2001) Beta-amyloid fibrils activate the C1 complex of complement under physiological conditions: evidence for a binding site for A beta on the C1q globular regions. J. Immunol. 167, 6374-6381.
161. Bradt, B.M., Kolb, W.P., and Cooper, N.R. (1998) Complement-dependent proinflammatory properties of the Alzheimer's disease beta-peptide. J. Exp. Med. 188, 431-438.
162. Wyss-Coray, T., Yan, F., Lin, A.H., Lambris, J.D., Alexander, J.J., Quigg, R.J., and Masliah, E. (2002) Prominent neurodegeneration and increased
163. Calabrese, G.C., Alberto, M.F., Tubio, R., Marani, M.M., Fernandez De Recondo, M.E., Lazzari, M., and Recondo, E.F. (2004) A small fraction of dermatan sulfate with significantly increased anticoagulant activity was selected by interaction with the first complement protein. Thromb. Res. 113, 243-250.
164. Kozlov, L.V., Belkin, Z.P., Bichucher, A.M., Batalova, T.N., and Diakov, V.L. (2003) [Comparative effects of complement inhibitors in vitro and in vivo experiments: an immunoenzyme method in studying subcomponent C1q inhibition and complement inhibition in model animals]. Biomed. Khim. 49, 284-290.
165. Lappegard, K.T., Fung, M., Bergseth, G., Riesenfeld, J., Lambris, J.D., Videm, V., and Mollnes, T.E. (2004) Effect of complement inhibition and heparin coating on artificial surface-induced leukocyte and platelet activation. Ann. Thorac. Surg. 77, 932-941.
166. Lappegard, K.T., Fung, M., Bergseth, G., Riesenfeld, J., and Mollnes, T.E. (2004) Artificial surface-induced cytokine synthesis: effect of heparin coating and complement inhibition. Ann. Thorac. Surg. 78, 38-44; discussion 44-35.
167. Tanzi, M.C. (2005) Bioactive technologies for hemocompatibility. Expert Rev. Med. Devices 2, 473-492.
168. Vaziri-Sani, F., Hellwage, J., Zipfel, P.F., Sjoholm, A.G., Iancu, R., and Karpman, D. (2005) Factor H binds to washed human platelets. J. Thromb. Haemost. 3, 154-162.
169. Villoutreix, B.O., Hardig, Y., Wallqvist, A., Covell, D.G., Garcia de Frutos, P., and Dahlback, B. (1998) Structural investigation of C4b-binding protein by molecular modeling: localization of putative binding sites. Proteins 31, 391-405.
170. Yu, H., Munoz, E.M., Edens, R.E., and Linhardt, R.J. (2005) Kinetic studies on the interactions of heparin and complement proteins using surface plasmon resonance. Biochim. Biophys. Acta 1726, 168-176.
171. Weiler, J.M., Edens, R.E., Linhardt, R.J., and Kapelanski, D.P. (1992) Heparin and modified heparin inhibit complement activation in vivo. J. Immunol. 148, 3210-3215.
172. Wuillemin, W.A., te Velthuis, H., Lubbers, Y.T., de Ruig, C.P., Eldering, E., and Hack, C.E. (1997) Potentiation of C1 inhibitor by glycosaminoglycans: dextran sulfate species are effective inhibitors of in vitro complement activation in plasma. J. Immunol. 159, 1953-1960.
173. Girardi, G., Redecha, P., and Salmon, J.E. (2004) Heparin prevents antiphospholipid antibody-induced fetal loss by inhibiting complement activation. Nat. Med. 10, 1222-1226.
174. Joseph, K., Shibayama, Y., Ghebrehiwet, B., and Kaplan, A.P. (2001) Factor XII-dependent contact activation on endothelial cells and binding proteins gC1qR and cytokeratin 1. Thromb. Haemost. 85, 119-124.
175. Kaplan, A.P., Joseph, K., and Shibayama, Y. (1997) Binding of activation of kinin-forming proteins on vascular endothelial cells. Immunopharmacology 36, 201-207.
176. Kaplan, A.P., Joseph, K., Shibayama, Y., Reddigari, S., and Ghebrehiwet, B. (2001) Activation of the plasma kinin forming cascade along cell surfaces. Int. Arch. Allergy Immunol. 124, 339-342.
177. Kaplan, A.P., Joseph, K., Shibayama, Y., Reddigari, S., Ghebrehiwet, B., and Silverberg, M. (1997) The intrinsic coagulation/kinin-forming cascade: assembly in plasma and cell surfaces in inflammation. Adv. Immunol. 66, 225-272.
178. Schmaier, A.H. (2008) The elusive physiologic role of Factor XII. J. Clin. Invest. 118, 3006-3009.
179. Schmaier, A.H. (2008) Assembly, activation, and physiologic influence of the plasma kallikrein/kinin system. Int. Immunopharmacol. 8, 161-165.
180. Schmaier, A.H. and McCrae, K.R. (2007) The plasma kallikrein-kinin system: its evolution from contact activation. J. Thromb. Haemost. 5, 2323-2329.
181. Schmaier, A.H. (1998) Plasma contact activation: a revised hypothesis. Biol. Res. 31, 251-262.
182. Colman, R.W. and Schmaier, A.H. (1997) Contact system: a vascular biology modulator with anticoagulant, profibrinolytic, antiadhesive, and proinflammatory attributes. Blood 90, 3819-3843.
183. DeLa Cadena, R.A., Majluf-Cruz, A., Stadnicki, A., Agosti, J.M., Colman, R.W., and Suffredini, A.F. (1996) Activation of the contact and fibrinolytic systems after intravenous administration of endotoxin to normal human volunteers: correlation with the cytokine profile. Immunopharmacology 33, 231-237.
184. Amara, U., Rittirsch, D., Flierl, M., Bruckner, U., Klos, A., Gebhard, F., Lambris, J.D., and Huber-Lang, M. (2008) Interaction between the coagulation and complement system. Adv. Exp. Med. Biol. 632, 71-79.
185. Naff, G.B. and Ratnoff, O.S. (1968) The enzymatic nature of C'1r. Conversion of C'1s to C'1 esterase and digestion of amino acid esters by C'1r. J. Exp. Med. 128, 571-593.
186. Ratnoff, O.D. and Naff, G.B. (1967) The conversion of C'IS to C'1 esterase by plasmin and trypsin. J. Exp. Med. 125, 337-358.
187. Ratnoff, O.D., Pensky, J., Ogston, D., and Naff, G.B. (1969) The inhibition of plasmin, plasma kallikrein, plasma permeability factor, and the C'1r subcomponent of the first component of complement by serum C'1 esterase inhibitor. J. Exp. Med. 129, 315-331.
188. Maas, C., Govers-Riemslag, J.W., Bouma, B., Schiks, B., Hazenberg, B.P., Lokhorst, H.M., Hammarstrom, P., ten Cate, H., de Groot, P.G., Bouma, B.N., and Gebbink, M.F. (2008) Misfolded proteins activate factor XII in humans, leading to kallikrein formation without initiating coagulation. J. Clin. Invest. 118, 3208-3218.
189. Casoli, T., Di Stefano, G., Giorgetti, B., Grossi, Y., Balietti, M., Fattoretti, P., and Bertoni-Freddari, C. (2007) Release of beta-amyloid from high-density platelets: implications for Alzheimer's disease pathology. Ann. N. Y. Acad. Sci. 1096, 170-178.
190. Chen, M., Inestrosa, N.C., Ross, G.S., and Fernandez, H.L. (1995) Platelets are the primary source of amyloid beta-peptide in human blood. Biochem. Biophys. Res. Commun. 213, 96-103.
191. Arai, T., Miklossy, J., Klegeris, A., Guo, J.P., and McGeer, P.L. (2006) Thrombin and prothrombin are expressed by neurons and glial cells and accumulate in neurofibrillary tangles in Alzheimer disease brain. J. Neuropathol. Exp. Neurol. 65, 19-25.
192. Viel, T.A., Lima Caetano, A., Nasello, A.G., Lancelotti, C.L., Nunes, V.A., Araujo, M.S., and Buck, H.S. (2008) Increases of kinin B1 and B2 receptors binding sites after brain infusion of amyloid-beta 1-40 peptide in rats. Neurobiol. Aging 29, 1805-1814.
193. Fabbro, S. and Seeds, N.W. (2009) Plasminogen activator activity is inhibited while neuroserpin is up-regulated in the Alzheimer disease brain. J. Neurochem. 109(2), 303-315.
194. Sarvari, M., Vago, I., Weber, C.S., Nagy, J., Gal, P., Mak, M., Kosa, J.P., Zavodszky, P., and Pazmany, T. (2003) Inhibition of C1q-beta-amyloid binding protects hippocampal cells against complement mediated toxicity. J. Neuroimmunol. 137, 12-18.
195. Caldwell, E.E., Andreasen, A.M., Blietz, M.A., Serrahn, J.N., VanderNoot, V., Park, Y., Yu, G., Linhardt, R.J., and Weiler, J.M. (1999) Heparin binding and augmentation of C1 inhibitor activity. Arch. Biochem. Biophys. 361, 215-222.
196. Caughman, G.B., Boackle, R.J., and Vesely, J. (1982) A postulated mechanism for heparin's potentiation of C1 inhibitor function. Mol. Immunol. 19, 287-295.
197. Mahley, R.W. (1988) Apolipoprotein E: cholesterol transport protein with expanding role in cell biology. Science 240, 622-630.
198. Deane, R., Sagare, A., Hamm, K., Parisi, M., Lane, S., Finn, M.B., Holtzman, D.M., and Zlokovic, B.V. (2008) apoE isoform-specific disruption of amyloid beta peptide clearance from mouse brain. J. Clin. Invest. 118, 4002-4013.
199. Rademakers, R., Cruts, M., and Van Broeckhoven, C. (2003) Genetics of early-onset Alzheimer dementia. TheScientificWorldJOURNAL 3, 497-519.
200. Strittmatter, W.J., Saunders, A.M., Schmechel, D., Pericak-Vance, M., Enghild, J., Salvesen, G.S., and Roses, A.D. (1993) Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease. Proc. Natl. Acad. Sci. U. S. A. 90, 1977-1981.
201. Slooter, A.J., Houwing-Duistermaat, J.J., van Harskamp, F., Cruts, M., Van Broeckhoven, C., Breteler, M.M., Hofman, A., Stijnen, T., and van Duijn, C.M. (1999) Apolipoprotein E genotype and progression of Alzheimer's disease: the Rotterdam Study. J. Neurol. 246, 304-308.
202. Petersen, R.C., Smith, G.E., Ivnik, R.J., Tangalos, E.G., Schaid, D.J., Thibodeau, S.N., Kokmen, E., Waring, S.C., and Kurland, L.T. (1995) Apolipoprotein E status as a predictor of the development of Alzheimer's disease in memory-impaired individuals. JAMA 273, 1274-1278.
203. Tierney, M.C., Szalai, J.P., Snow, W.G., Fisher, R.H., Nores, A., Nadon, G., Dunn, E., and St. George-Hyslop, P.H. (1996) Prediction of probable Alzheimer's disease in memory-impaired patients: a prospective longitudinal study. Neurology 46, 661-665.
204. Weisgraber, K.H. and Shinto, L.H. (1991) Identification of the disulfide-linked homodimer of apolipoprotein E3 in plasma. Impact on receptor binding activity. J. Biol. Chem. 266, 12029-12034.
205. Bazin, H.G., Marques, M.A., Owens, A.P., 3rd, Linhardt, R.J., and Crutcher, K.A. (2002) Inhibition of apolipoprotein E-related neurotoxicity by glycosaminoglycans and their oligosaccharides. Biochemistry 41, 8203-8211.
206. Dong, J., Peters-Libeu, C.A., Weisgraber, K.H., Segelke, B.W., Rupp, B., Capila, I., Hernaiz, M.J., LeBrun, L.A., and Linhardt, R.J. (2001) Interaction of the N-terminal domain of apolipoprotein E4 with heparin. Biochemistry 40, 2826-2834.
207. Libeu, C.P., Lund-Katz, S., Phillips, M.C., Wehrli, S., Hernaiz, M.J., Capila, I., Linhardt, R.J., Raffai, R.L., Newhouse, Y.M., Zhou, F., and Weisgraber, K.H. (2001) New insights into the heparan sulfate proteoglycan-binding activity of apolipoprotein E. J. Biol. Chem.276, 39138-39144.
208. Sadowski, M., Pankiewicz, J., Scholtzova, H., Ripellino, J.A., Li, Y., Schmidt, S.D., Mathews, P.M., Fryer, J.D., Holtzman, D.M., Sigurdsson, E.M., and Wisniewski, T. (2004) A synthetic peptide blocking the apolipoprotein E/beta-amyloid binding mitigates beta-amyloid toxicity and fibril formation in vitro and reduces beta-amyloid plaques in transgenic mice. Am. J. Pathol. 165, 937-948.
209. Saito, H., Dhanasekaran, P., Nguyen, D., Baldwin, F., Weisgraber, K.H., Wehrli, S., Phillips, M.C., and Lund-Katz, S. (2003) Characterization of the heparin binding sites in human apolipoprotein E. J. Biol. Chem. 278, 14782-14787.
210. Shuvaev, V.V. and Siest, G. (2000) Heparin specifically inhibits binding of apolipoprotein E to amyloid beta-peptide. Neurosci. Lett. 280, 131-134.
211. Dudas, B., Cornelli, U., Lee, J.M., Hejna, M.J., Walzer, M., Lorens, S.A., Mervis, R.F., Fareed, J., and Hanin, I. (2002) Oral and subcutaneous administration of the glycosaminoglycan C3 attenuates Abeta(25-35)-induced abnormal tau protein immunoreactivity in rat brain. Neurobiol. Aging 23, 97-104.
212. Dudas, B., Rose, M., Cornelli, U., Pavlovich, A., and Hanin, I. (2008) Neuroprotective properties of glycosaminoglycans: potential treatment for neurodegenerative disorders. Neurodegener. Dis. 5, 200-205.